Cemiplimab, which acts as a PD-1 immune checkpoint inhibitor, has been approved by the FDA for treating locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) [157]. This evidence concerns the gene PDCD1 and skin squamous cell carcinoma.